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Background: Cardiovascular disease (CVD) is a major cause of premature death in
patients with psychotic disorders, where dyslipidemia occurs frequently. In the
pathogenesis of these serious mental disorders, a low-grade inflammation seems to be
a possible contributor. Concurrently, systemic inflammation and its interplay with
dyslipidemia is a central driver in the pathogenesis of CVD. We hypothesize that
evaluation of atherogenic lipid ratios together with inflammatory markers reflecting
different inflammatory pathways with relevance for atherogenesis, could give novel
information on immune-related mechanisms involved in early CVD risk in patients with
psychotic disorders.
Methods: As a measure for CVD risk we calculated atherogenic lipid ratios using
established sex-specific cut-offs: Total cholesterol/high-density lipoprotein; HDL-c (TC/
HDL) and triglyceride/HDL-c (TG/HDL) were evaluated in 571 schizophrenia (SCZ) and
247 bipolar disorder (BD) patients, and in 99 healthy controls (HC). In addition, as a
measure of low-grade inflammation, we measured fasting plasma levels of nine stable
atherogenic inflammatory markers in patients (SCZ, BD) and in HC. The elevated
inflammatory markers and CVD risk in patients, as reflected by TC/HDL and TG/HDL,
were further assessed in multivariable analyses adjusting for comorbid cardio-metabolic
risk factors.g July 2020 | Volume 11 | Article 6721
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Frontiers in Psychiatry | www.frontiersin.orResults: A markedly higher proportion (26%–31%) of patients had increased TC/HDL
and TG/HDL ratios compared with HC. Plasma levels of high-sensitivity C-reactive protein
(hs-CRP) and myeloperoxidase (MPO) were higher (p<0.05, p<0.001) in patients with
psychotic disorders than in HC, and hs-CRP and MPO were independently associated
with atherogenic lipid ratios in the multivariable analyses.
Conclusions:Our findings suggest that low-grade inflammation and abnormal neutrophil
activation may cause increased CVD risk in patients with psychotic disorders. These
mechanisms should be further examined to determine the potential for development of
novel risk evaluation strategies.Keywords: CVD risk, dyslipidemia, inflammatory biomarkers, schizophrenia, bipolar disorderINTRODUCTION
Psychotic disorders are characterized by significant comorbid
cardiometabolic risk (1, 2), and cardiovascular disease (CVD)
mortality is elevated in patients with psychotic disorders.
Compared with the general population, the risk of cardiovascular
mortality is almost 2-fold in bipolar disorder and 2 to 3-fold in
schizophrenia (3–5). Undiagnosed CVD prior to cardiovascular
death is more common in psychotic disorders than in the general
population (6).
Furthermore, dyslipidemia has frequently been reported in
patients with severe mental disorders (1, 2). It is well known that
second generation antipsychotic drugs (SGA) are associated with
dyslipidemia and other metabolic side effects (7), but long-term
antipsychotic treatment is contradictorily associated with
reduced CVD mortality (8).
Atherogenic lipid ratios such as the total cholesterol/high-
density lipoprotein; HDL-c (TC/HDL) and triglyceride/HDL-c
(TG/HDL) have been shown to hold greater predictive value for
CVD risk in individuals without symptomatic CVD than the isolated
lipid parameters used independently (9, 10). Although increased TC
and TG and reduced HDL-c have been reported (1, 2), these ratios
have scarcely been investigated in psychiatric disorders.
It is well known that lipid accumulation together with low-grade
inflammation leadtoachronicvascularremodelinganddevelopment
of atherosclerosis in the arteries (11). An increasing number of novel
inflammatory biomarkers that predict cardiovascular risk have
recently been identified. These biomarkers are therefore relevant to
investigate in patients with psychotic disorders, where a low-grade
inflammation is a possible pathogenic contributor (12, 13).
Based on the emerging role of inflammation and its interaction
with dyslipidemia in the progression of atherosclerotic disease,
we hypothesize herein that evaluation of atherogenic lipid
ratios together with inflammatory markers reflecting different
inflammatory pathways with relevance for atherogenesis, could give
novel information on immune-related mechanisms involved in the
premature CVD risk in patients with psychotic disorders.
Our specific aims of this study were three-fold. Firstly, we
evaluate whether the distribution of pro-atherogenic lipid ratios
differ between a large cohort of patients with psychosis compared
to healthy controls (HC). Secondly, we investigate whether theg 2following inflammatory markers are dysregulated in patients
with psychotic disorders versus HC:
• General down-streammarkers of inflammation: High-sensitivity
C-reactive protein (hs-CRP) (14) and glycoprotein 130 (gp130, a
member of the interleukine-6 receptor family) (15).
• Markers of vascular inflammation, calcification, and endothelial
function: Pentraxin 3 (PTX3) (16), osteoprotegerin (OPG) (17),
and von Willebrand factor (vWF) (18).
• Markers related to fibrosis and extracellular matrix (ECM)
remodeling: Galectin 3 (19) and Cathepsin S (20).
• Marker of neutrophil activation: Myeloperoxidase (MPO) (21).
• Marker of vascular apoptosis; Insulin-like growth factor-
binding protein 4 (IGFBP4) (22).
Thirdly and lastly, we further investigate whether CVD risk as
estimated by lipid ratios is associated with any upregulated
inflammatory markers identified in the patient population.
This study presents a detailed and thorough analysis of these three
topics on a uniquely large cohort of patients with psychotic disorders.METHODS
Design and Participants
The current study is part of the ongoing Thematically Organized
Psychosis (TOP) Study at the Norwegian Centre for Mental
Disorders Research (NORMENT). The TOP Study includes
patients from both outpatient clinics and hospitals in the Oslo,
Trondheim, and Lillehammer regions in Norway. Inclusion
criteria in the TOP Study are: diagnosis of severe mental disorder,
age between18–65 years and ability to give written informed
consent. The healthy controls (HC), between 18–60 years old,
were randomly selected from statistical records (www.ssb.no) in
the Oslo region. All participants have given informed written
consent. The study was approved by the Norwegian Scientific
Ethical Committees and the Norwegian Data Protection Agency.
Sample
The sample used for the current cross-sectional study consists of
818 patients with severe mental disorders and 99 healthy controlsJuly 2020 | Volume 11 | Article 672
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Study from 2002 until 2013. In this sample, 571 patients had a
schizophrenia spectrum disorder (SCZ: schizophrenia, schizoaffective
disorder, schizophreniform disorder and psychotic disorder not
otherwise specified), while 247 patients had a bipolar spectrum
disorder (BD: bipolar I, bipolar II and bipolar disorder not
otherwise specified). The SCZ and BD groups combined are
hereafter referred to as the “all patients” group.
Participants with non-fasting blood samples, autoimmune or
inflammatory diseases, on-going cancer, on-going infections, C-
reactive protein (CRP) >20 mg/L of any reason, insulin levels
>400 pmol/L, or participants receiving treatment with immune
modulating drugs were excluded.
Clinical Assessments
All patients underwent a thorough diagnostic evaluation based
on the Structured Clinical Interview in Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition (DSM-IV) axis I Disorders
(SCID-1). The Positive and Negative Syndrome Scale (PANSS), the
YoungManiaRating scale (YMRS), and theCalgaryDepressionScale
for Schizophrenia (CDSS) were used for evaluations of the symtoms,
and the functioning was assessed using the functioning score of the
split versionof theGlobalAssessmentof theFunctioningScale (GAF-
F). The inter-investigator diagnostic agreement has previously been
evaluated to a satisfying level of 82%, with overall ĸ=0.77 (CI 0.60-
0.94) (23).
Body mass index (BMI) (kg/m²) was calculated based on
height and weight measured by standard methods. For weight
digitally calibrated weights were used. Blood pressure was
measured using a manual device under standard conditions.
The HC were interviewed using the Primary Care Evaluation of
Mental Disorders (PRIME MD) to assess current or previous
history of severe mental disorder themselves or in their family.
Blood Samples
The methodology used for drawing, processing and storage of
blood samples have been described previously (24). Some of
these biological markers have been reported previously by us in
relation to other outcome measures (25–30).
Lipid Risk Factors
Plasma levels of total cholesterol (TC), triglyceride (TG), high-
density lipoprotein (HDL-c), and low-density lipoprotein (LDL-c)
were measured at the Department of Medical Biochemistry, Oslo
University Hospital. TC, TG, and HDL-c were directly measured
using an Integra 800 instrument from Roche Diagnostics,
according to standard methods. LDL-c was calculated by
Friedewald formula at the Department of Medical Biochemistry,
Oslo University Hospital. This method changed during the study
to direct measurement of LDL-c using an Integra 800 instrument
from Roche Diagnostics.
Inflammatory Markers
Plasma levels of hs-CRP, gp130, PTX3, OPG, vWF, Galectin 3,
Cathepsin S, MPO, and IGFBP4 were measured by enzyme
immunoassays (EIA) in duplicate using commercially available
antibodies (R&D Systems, Minneapolis, MN, USA) in a 384Frontiers in Psychiatry | www.frontiersin.org 3format using a combination of a SELMA (Jena, Germany)
pipetting robot and a BioTek (Winooski, VT, USA) dispenser/
washer. Absorption was read at 450 nm with wavelength
correction set to 540 nm using an ELISA plate reader (Bio-
Rad, Hercules, CA, USA). Intra- and inter-assay coefficients of
variation were <10% for all EIAs. For immunoassays blood was
drawn using EDTA vials and the plasma was isolated the next
working day and stored at -80°C. As plasma samples were
collected over a long period, we evaluated potential degradation
by comparing CRP measured continuously during samples
collection and CRP measured during the bulk analysis of the
other inflammatory markers. These CRPmeasurements correlated
strongly (r=0.86) and both correlated similarly to time since
sampling (r=0.17). Thus, the positive and similar association
with sample time for CRP measured during sample collection
and during bulk analysis argue against an effect of sample
degradation during storage.
Insulin Resistance
Plasma levels of insulin and glucosewere analyzed at theDepartment
of Medical Biochemistry, Oslo University Hospital. Insulin was
analyzed at the Hormone Laboratory by radioimmunoassay (RIA)
using standard methods. Glucose levels were analyzed using
standardized platforms from Roche Diagnostics. We estimated
insulin resistance using the Homeostasis Model Assessment for
Insulin Resistance (HOMA-IR) (31). As the calculation is valid only
with insulin levels <400 pmol/L, participants with higher levels were
excluded (N=11 patients).
Blood sampling was performed between 8 am and 11 am for
most of the participants. All participants included in this study
were fasting during blood collection.
Medication
Information on the use of prescribed medications including
antipsychotics, immune modulating medication and statins
used by patients was assessed by clinical interview and hospital
records. “Defined daily dose” (DDD) was calculated according to
the World Health Organization (WHO) principles. We calculated
the individual total DDD based on antipsychotic polypharmacy.
The DDD is the assumed average maintenance dose per day for a
drug used for its main indication in adults and provide a fixed unit
of measurement independent of dosage form (http://www.whocc.
no/atc_ddd_index/).
Statistical Analyses
All statistical analyses were done using the SPSS software
package for Windows, version 25.0 (SPSS Chicago. USA). All
analyses were two-tailed with a level of significance set at p˂0.05.
All skewed data was log-transformed prior to further analyses.
The cardio-metabolic risk was estimated using established
atherogenic lipid ratios including TG/HDL and TC/HDL, with sex-
dependent cut-offs established elsewhere (9, 10). Atherogenic lipid
ratios were calculated, and enhanced cardio-metabolic risk was
defined by (based on SI units, mmol/L): TC/HDL, male >5, female
>4.5 (10); TG/HDL, male >1.53, female >1.09 (9). Differences in the
proportion of individuals at risk between diagnostic groups were
assessed using the chi-square test (unadjusted analysis). We thenJuly 2020 | Volume 11 | Article 672
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analysis (adjusted analysis).
Differences in levels of inflammatory biomarkers between HC
and diagnostic groups (i.e., SCZ and BD) were analyzed by
multivariate analysis of covariance (MANCOVA) adjusting for
demographics (age, sex, BMI).
Finally, in inflammatory markers that were elevated in
patients (hs-CRP and MPO), the unadjusted and multivariable
adjusted estimated atherogenic risk (i.e., based on lipid ratios)
within the total patient population (i.e., SCZ and BD combined),
and within diagnostic groups (i.e., SCZ and BD analyzed
separately), were assessed using logistic regression. In these
analyses, TC/HDL or TG/HDL were included as the dependent
variable and hs-CRP or MPO were included as covariates in
block 1 (unadjusted analysis). Further adjustments for conventional
CVD risk factors; age, sex, BMI, insulin resistance, smoking, systolic
blood pressure, and anti-psychotic treatment (DDD), were
performed in block 2 (adjusted analysis). An example of a fully
adjusted model is shown in Figure 2C.RESULTS
Sample Characteristics
Theclinical characteristicsof thestudypopulationareshowninTable
1. The mean age and sex distribution in the patient group compared
withHCweremainly the samewhen looking at the patient group as a
whole. A subgroup analysis revealed that patients with BD were
significantly older and more frequently female compared both to
HC and patients with SCZ. The patients in general had significantly
higherBMI,particularlysowithinSCZ.Therewasahigherproportion
of non-European origin in patients compared to HC. The majority
(78%)ofpatients receivedpsychotropic drug treatment,with ahigher
DDD in SCZ than in BD.
Evaluation of lipids revealed a dysregulated profile with
higher TC, LDL-c, and TG and lower HDL-c in the patients,
and these differences were most prominent in patients with SCZ.
Furthermore, patients, and in particular those with SCZ, had a
higher degree of insulin resistance as estimated by HOMA-IR
compared to HC (Table 1).
Pro-Atherogenic Lipid Ratios in Patients
With Psychotic Disorders
To further evaluate the unfavorable lipid profile in patients with
psychotic disorders, we calculated pro-atherogenic risk ratios
based on lipid levels and assessed risk of CVD based on establish
sex-specific cut-offs. Since indirectly measured LDL is derived
from TC, and since TC/HDL ratio also is an established predictor
of CVD risk, we focused the analyses on TC/HDL and TG/HDL.
The patient group as a whole had a markedly higher proportion
with enhanced TC/HDL (26.2%) and TG/HDL (30.5%)
compared to healthy controls (9.2% and 8.2% for TC/HDL and
TG/HDL, respectively). The unadjusted risk for an elevated TC/
HDL was 3.35 [CI 1.65–6.80], p<0.001 in patients compared to
controls, which persisted in age, sex, and BMI adjusted analysis,
2.69 [CI 1.29–5.60], p=0.008. Corresponding figures for TG/Frontiers in Psychiatry | www.frontiersin.org 4HDL were 4.77 [CI 2.27-10.01], p<0.001 in unadjusted and 3.16
[CI 1.47–6.80], p=0.003 in adjusted analysis.
Figure 1 shows the distribution of these lipid ratios according
to diagnosis (BD, SCZ) and sex. Increased lipid ratios compared
to HC were observed in both patient groups and sexes with a
higher frequency in men and in patients with SCZ. Of note, the
proportion of female patients with an elevated TG/HDL ratio was
higher (23%–29%) than for TC/HDL (14%–21%), while these
frequencies were similar in male patients (32%–34%).
Inflammatory Markers in Patients With
Psychotic Disorders
Patients as a whole were characterized by higher levels of hs-CRP
(f=3.19, p=0.042) than HC in age, sex and BMI adjusted
multivariate analysis of covariance (MANCOVA), shown in
Table 2, with the highest levels in patients with SCZ (f=4.62,
p=0.032) compared to HC. Circulating MPO as marker of
neutrophil activation was markedly higher in patients; both in
SCZ (f=16.01, p=7.1x10-5) and in BD (f=11.01, p=0.001)
compared to HC. In contrast, we observed lower gp130 with a
similar reduction in patients with BD (f=10.04, p=0.002) and
SCZ (f=7.79, p=0.005) compared to HC. A similar association
was observed for Galectin 3 in SCZ (f=40.5 p=4.2x10-10) and in
BD (f=62.8, p=4.4x10-14) compared to HC, and for Cathepsin S
in SCZ (f=6.91, p=0.009), and with the lowest levels in patients
with BD (f=19.91, p=1.1x10-5), compared to HC. No significant
differences were observed for PTX3, OPG, IGFBP4, and vWF,
although low vWF levels were noted in patients with BD (f=5.94,
p=0.015) compared to HC. Within the patient population (where
smoking status was available), there were no significant
difference in levels of inflammatory markers between smokers
and non-smokers, except with respect to vWF where smokers
had higher levels (95 AU in non-smokers vs. 108 AU in
smokers, p=0.025).
Association Between MPO, hs-CRP, and
Atherogenic Lipid Ratios
Odds ratios (OR) were for these analyses based on log-transformed
standardized values, and represent a one standard deviation (SD)
increase in the analyzed marker. Figure 2 shows unadjusted and
adjustedlogisticregressionanalysis forTC/HDL(Figure2A)andTG/
HDL(Figure2B) ratios above thecut-offforCVDrisk.Data are show
for all patients and within diagnostic sub-groups (i.e., SCZ or BD).
As shown in Figure 2, unadjusted logistic regression analysis
revealed a strong association between higher hs-CRP levels and
CVD risk as reflected by elevated atherogenic lipid ratios, with OR
1.78 (95% CI 1.47–2.16, p<0.001) for TC/HDL (Figure 2A) and OR
1.91 (95% CI 1.58–2.30, p<0.001) for TG/HDL (Figure 2B). This
association, although attenuated, remained significant in adjusted
logistic regressionanalysis (OR1.31forTC/HDLandOR1.40forTG/
HDL). Multivariable adjustment included insulin resistance (IR),
smoking, anti-psychotic treatment (DDD), age, sex, BMI, hs-CRP
(CRP),andMPO.TheassociationwasstrongerinSCZpatients,where
itremainedsignificantinadjustedanalysiswithOR1.49(95%CI1.14–
1.96, p=0.004), while the association was not significant in BD
following adjustment.July 2020 | Volume 11 | Article 672
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FIGURE 1 | Increased cardiovascular risk in psychotic disorders as reflected by atherogenic lipid ratios. Distribution of the total cholesterol/high-density lipoprotein
(TC/HDL) (A) and triglyceride/HDL-c (TG/HDL) (B) ratios in healthy controls, patients with bipolar disorder or schizophrenia according to sex. The pie diagram shows
the number of individuals with ratios above the risk cut-off.TABLE 1 | Demographics of the study population.
Clinical parameters HC(n=99) All patients(n=818) BD(n=247) SCZ(n=571) Post hoc
%(n) %(n) %(n) %(n)
Sex (male) 61.6 (61) 52.8 (432) 39.3 (97) 58.7 (335) SCZ,HC>BD
Ethnicity (European) 98.0 (97) 82.2 (672)*** 89.1 (220) 79.2 (452) HC>BD,SCZ
Smoking status (daily use) N/A 46.2 (367) 43.8 (106) 47.3 (261) n.s.
Statin use 0 (0) 1.7 (14) 2.0 (5) 1.6 (9) n.s.
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Anti-psychotic treatment (DDD) N/A 0.96 (0.96) 0.5 (0.77) 1.13 (0.97) SCZ>BD
Age 30 (8) 31 (11) 34 (12) 30 (10) BD>SCZ,HC
Cardiometabolic risk factors
HOMA-IR 2.7 (1.5) 3.7 (2.6)** 3.4 (2.2) 3.8 (2.7) SCZ>BD,HC
HDL-c(mmol/L) 1.51 (0.46) 1.36 (0.43)** 1.46 (0.48) 1.31 (0.40) HC,BD>SCZ
LDL-c (mmol/L) 2.85 (0.90) 3.14 (0.95)** 3.02 (0.90) 3.19 (0.96) SCZ>BD,HC
Total-c (mmol/L) 4.70 (0.93) 5.10 (1.07)** 5.06 (1.06) 5.11 (1.08) SCZ,BD>HC
Triglycerides(mmol/L) 1.04 (0.44) 1.46(1.10)*** 1.39 (1.13) 1.49 (1.08) SCZ,BD>HC
BMI 23.9 (3.2) 26.3 (5.0)*** 25.7 (4.4) 26.5 (5.3) SCZ,BD>HC
Symptom scores
PANSS total N/A 58 (17) 46 (11) 63 (17) SCZ>BD
CDSS total N/A 5.5 (4.8) 4.8(4.9) 5.7 (4.8) SCZ>BD
YMRS total N/A 4.8 (5.2) 3.9 (5.3) 5.3 (5.0) SCZ>BD
GAF-S N/A 46 (13) 56 (12) 42 (11) BD>SCZ
GAF-F N/A 46 (12) 53 (13) 44 (11) BD>SCZFrontiers in Psychiatry | www.frontiersin.org 5 July 2020 | Volume 11Analyzed with ANOVA for continuous variables and chi-square test for categorical variables. HC, healthy controls; BD, bipolar spectrum; SCZ, schizophrenia spectrum; n, number; DDD,
defined daily dose; SD, standard deviation; HOMA-IR, homeostasis model assessment for insulin resistance; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein
cholesterol; Total-c, total cholesterol; mmol/L, millimoles per liter; BMI, body mass index; PANSS, Positive and Negative Syndrome Scale; CDSS, Calgary Depression Scale for
Schizophrenia; YMRS, Young Mania Rating Scale; GAF-S, Global Assessment of Functioning-symptoms; GAF-F, Global Assessment of Functioning- functions; N/A, not applicable; n.s.,
not significant; *p<0.05 **p<0.01 ***p<0.001 vs. healthy controls.| Article 672
Reponen et al. Cardiovascular Risk in Psychotic DisordersThe association between MPO and CVD risk in patients was
more modest and only present for the TC/HDL ratio with OR
1.40 (95% CI 1.12–1.76 p=0.004), but persisted after
multivariable adjustment with OR 1.25 (95% CI 1.04–1.52,
p=0.025). The association appeared at the same level in SCZ
and BD, but was more attenuated by adjustment in BD and thus
only statistically significant in SCZ in adjusted analysis OR 1.29
(95% CI 1.03–1.65, p=0.038).
As both hs-CRP and MPO were associated with increased
TC/HDL, we also evaluated these markers together. Figure 2C
shows that both proteins were associated with an increased TC/
HDL ratio in multivariable adjusted analysis.DISCUSSION
Our study, evaluating a large number of relatively young (mean
age = 31 years) patients with psychotic disorders, shows that this
patient group is characterized by a markedly higher CVD risk.
This is reflected by a larger proportion of individuals with
elevated atherogenic lipid ratios among patients with psychotic
disorders compared to HC, in particular in male patients and inFrontiers in Psychiatry | www.frontiersin.org 6patients with SCZ. Plasma levels of hs-CRP, a reliable downstream
markerof inflammation, andMPO,amarkerofneutrophil activation
and oxidative stress, were higher in patients with psychotic disorders,
and independently associated with unfavorable lipid ratios in
multivariable analysis adjusting for conventional CVD risk factors.
Thesedata suggest that low-grade inflammation in combinationwith
an atherogenic lipid profilemay cause increasedCVDrisk in patients
with psychotic disorders.
Dyslipidemia has frequently been reported in patients with
severe mental disorders, in both medicated and drug naïve
patients (32). We demonstrated relatively stable lipid levels
during longitudinal testing (5 years follow-up) in patients with
schizophrenia and schizoaffective disorders suggesting that lipid
abnormalities may be related to core disease mechanisms (33) in
addition to antipsychotic medication (7). Regardless of cause,
dyslipidemia and metabolic abnormalities are closely associated
with an enhanced risk of cardiovascular outcomes. In this regard,
atherogenic lipid ratios such as the TC/HDL and TG/HDL hold
greater predictive value in individuals without symptomatic
CVD than the independent lipid parameters (10). We were
unable to find age and sex distributed reference data on the
prevalence of increased ratios in the general population.TABLE 2 | Level of inflammatory markers (MANCOVA) after adjustment for age, BMI, and sex.
HC(n=99) All patients(n=818) BD(n=247) SCZ(n=571)
hsCRP (mg/L) 1.78 (1.44, 2.19) 2.18 (2.02, 2.36)* 1.96 (1.70, 2.26) 2.29 (2.09, 2.51)*
PTX3 (ng/ml) 2.97 (2.53, 3.49) 3.01 (2.84, 3.19) 3.03 (2.72, 3.37) 3.01 (2.80, 3.23)
OPG (ng/ml) 1.32 (1.24, 1.40) 1.35 (1.32, 1.38) 1.36 (1.31, 1.42) 1.35 (1.31, 1.38)
vWF (AU) 82.6 (70.8, 96.6) 72.8 (68.8, 77) 67.3 (60.7, 74.7)* 75.3 (70.4, 80.7)
gp130 (ng/ml) 234 (224, 243) 217 (214, 220)*** 214 (208, 220)** 218 (214, 222)**
GAL3 (ng/ml) 5.47 (4.56, 6.56) 2.67 (2.50, 2.86)*** 2.33 (2.06, 2.63)*** 2.84 (2.62, 3.08)*** †
CatS (ng/ml) 5.99 (5.57, 6.41) 5.35 (5.19, 5.50)** 4.99 (4.71, 5.26)*** 5.51 (5.32, 5.69)** †
MPO (ng/ml) 179 (148, 218) 275 (256, 295)*** 294 (259, 335)*** 266 (245, 290)***
IGFBP4 (ng/ml) 161 (151, 170) 165 (161, 168) 166 (160, 173) 164 (160, 168)July 2020 | VoData are presented as estimated marginal means with 95% confidence interval. *p<0.05 **p<0.01 ***p<0.001 vs. healthy controls; †p<0.01 vs. bipolar disorder. MANCOVA, multivariate
analysis of covariance; BMI, body mass index; n, number; hs-CRP, high sensitivity c-reactive protein; PTX3, pentraxin 3; OPG, osteoprotegerin; vWF, von Willebrand factor; gp130,
glycoprotein 130; Gal3, galectin 3; CatS, cathepsin S; MPO, myeloperoxidase; IGFBP4, insulin-like growth factor-binding protein 4; mg/L, milligrams per liter; ng/mL, nanograms per
milliliter; AU, arbitrary units.A B C
FIGURE 2 | Association between inflammatory markers and cardiovascular disease (CVD) risk as reflected by atherogenic lipid ratios in patients with psychotic disorders.
Univariate (blue) and multivariable (red) logistic regression of hs-CRP (CRP) (top) and myeloperoxidase (MPO) (bottom) as predictors of dysregulated lipid ratios TC/HDL
(A) and TG/HDL (B). Multivariable adjustment for total cholesterol/high-density lipoprotein (TC/HDL) is shown in (C) and included insulin resistance (IR), smoking, anti-
psychotic treatment (DDD), age, sex, BMI, hs-CRP (CRP), and MPO. Odds ratios (OR) are expressed as log-transformed per SD change in marker.lume 11 | Article 672
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and women in our study corresponded to the 50 percentile for 30
year-olds in a large contemporary population-based Dutch
cohort study (34), suggesting that although limited in size the
proportion of controls with increased lipid ratios in our study is
comparable to similar European populations. This supports our
data indicating a markedly enhanced CVD risk in this young
population of patients with SCZ and BD, which may be related to
the decreased life expectancy and plausibly increasing mortality
due to cardiovascular causes in such patients (5, 35, 36). The
higherproportionofpatientswithanelevatedTG/HDL,compared to
TC/HDL, (30.5% vs. 26.2%) in our study is compatible with the
metabolic phenotype in these patients such as insulin resistance.
Indeed, an increased TG/HDL ratio has been shown to closely
correlate with insulin resistance in SCZ (37) as well as with the
presence of small dense LDL particles which are particularly
atherogenic (37, 38).
Theinterplaybetweendyslipidemiaandchronic inflammationare
hallmarks of atherosclerotic progression (39).CRP is the prototypical
acute phase serum protein that rises rapidly in response to
inflammation, but also represents the most robust marker of
subclinical chronic inflammation. Chronic elevated levels have
repeatedly been associated with persistent auto-inflammatory
processes and an increased risk of future cardiovascular events in the
general population (14, 40), and with CVD risk in patients with
psychotic disorders (41–44). Our finding that elevated hs-CRP was
associated with CVD risk as reflected by the TC/HDL and TG/HDL
also in adjusted analysis including important cardio-metabolic risk
factors, support these previous studies. Furthermore, this association
wasstrongerandonlysignificantafter fullmultivariableadjustment in
SCZ suggesting a stronger impact of inflammatory dysregulation on
CVD risk in these patients. However, although hs-CRP by reflecting
the general inflammatory burden related to important demographics
such as insulin resistance and BMI (45, 46) represents a reliable risk
markerofCVD,it is lessuseful inpinpointingspecificdysregulationof
inflammation that may be linked to CVD risk.
A major finding in our study was the markedly increased
MPO levels in both SCZ and BD that were significantly
associated with the TC/HDL ratio, also in adjusted analysis for
SCZ. MPO is a reliable marker of neutrophil activation. These
cells have recently received renewed interest with regard to
atherosclerosis due to the variety of active substances they may
release from granules, including reactive oxygen species promoting
oxidation of lipoproteins, microparticles, and MPO that further are
related to neutrophil extracellular traps (NETs). Aberrant neutrophil
effector functions and increased circulating levels of inflammatory
neutrophil effectorpeptides, suchasalpha-defensinshavebeen linked
toSCZpathogenesis (47)andmayrepresentabridgingfactorbetween
atherosclerosisandinflammation(48).Indeed,elevatedlevelsofMPO
have been associated with coronary artery disease (CAD) (21) and
predict risk inacutecoronarysyndromes(49).However, less isknown
on the role of MPO in individuals without symptomatic CVD, but
epidemiologic studies demonstrate thatMPOmaypredict future risk
of coronary artery disease (50). Furthermore, elevated neutrophil
counts have been reported in BD and SCZ (51–53) and based on the
increasedMPOlevelsobserved inourstudy, it is tempting tospeculateFrontiers in Psychiatry | www.frontiersin.org 7that abnormalities in neutrophil activation could represent an early
event in the progression ofCVD in patients with psychotic disorders.
ThestrongerassociationwiththeTC/HDLcomparedtotheTG/HDL,
could suggest that the enhanced MPO is more directly linked to
atherogenesis and not only amarker of this process.
We were unable to detect differences in a number of markers
linked to vascular inflammation and CVD such as vWF (18),
OPG (17), PTX3 (16), while levels of fibrosis and ECM
remodeling markers such as Galectin 3 (19) and Cathepsin S
(20) were lower, which may further support our hypothesis
regarding dysregulated neutrophil effector functions and a
consequent low-grade inflammatory “background”. These
markers have repeatedly been associated with risk of adverse
cardiovascular outcomes, but have mainly been investigated in
patients with stable atherosclerotic disease. However, the
association with CVD risk in patients without established CVD
may be different than in patients with symptomatic CVD
concerning both the strength and potentially the direction of
association (54). Based on the relatively young age of our
population, vascular inflammation and ECM remodeling,
which accelerate during atherogenesis, may not yet be
activated. However, we are not able to conclude with respect to
this without following the same patient group over time.LIMITATIONS
This study had a cross-sectional design, making the causality
described suggestive.
As fasting status can affect levels of the inflammatory
markers, glucose, and lipid metabolism, we focused this study
on fasting blood samples. This excluded 435 non-fasting controls
and limited our control population to n=99, and gave uneven
group size compared to the patient population (n=818). The
relatively high portion of non-fasting participants in the initial
control group was mostly due to their busy everyday lives,
making it challenging to schedule blood sampling in the
morning. These controls are used in other studies performed
by the group. Furthermore, looking at differences between our
patient group and HC, the majority of the healthy controls in the
current sample are young and well-functioning, with a lower
BMI than the patients, possibly underestimating the impact of
lifestyle factors on dysregulation of some inflammatory markers.
The smoking status is not available for our healthy controls.
However, comparing inflammatory markers within the patient
population, only vWF was significantly affected with higher
levels in smokers. Also, while the effect of smoking on
inflammation is less documented, the effect of smoking on
CVD risk is known. Therefore, since we had smoking status in
our patients, we were able to adjust for smoking when evaluating
CVD risk. Future studies should include control groups that are
better matched with the patient group in regard to their
metabolic status. Finally, in our study, only 14 patients were
using lipid-lowering agents, thus our sample was statistically
underpowered to address the issue if these agents can be used as
an early intervention to reduce CVD risk.July 2020 | Volume 11 | Article 672
Reponen et al. Cardiovascular Risk in Psychotic DisordersCONCLUSION
Patients with psychotic disorders have a markedly higher CVD
risk compared to healthy controls as reflected by atherogenic
lipid ratios, and the increased risk is associated with elevated hs-
CRP andMPO reflecting subclinical inflammation and abnormal
neutrophil activation in such patients. These findings support
that low-grade inflammation may cause increased CVD risk in
patients with psychotic disorders. These mechanisms should be
further examined to determine the potential for treatment targets
or development of novel risk evaluation strategies.DATA AVAILABILITY STATEMENT
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